AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for...

Related Keywords

Japan ,Mohamed Zaki ,Genmab Duobody ,Instagram ,Linkedin ,Macrophage Propertiesj Immunol ,Twitter ,Drug Administration ,Exchange Commission ,Youtube ,Allergan ,Development Of Novel Anti ,European Medicines Agency ,Facebook ,Marketing Authorization Application ,Biologics License Application ,Diffuse Largeb Cell Lymphoma ,Largeb Cell Lymphoma ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,Abbvie ,